1. Personalized computational heart models with T1-mapped fibrotic remodeling predict sudden death risk in patients with hypertrophic cardiomyopathy.
- Author
-
O'Hara RP, Binka E, Prakosa A, Zimmerman SL, Cartoski MJ, Abraham MR, Lu DY, Boyle PM, and Trayanova NA
- Subjects
- Adult, Aged, Cardiomyopathy, Hypertrophic complications, Cardiomyopathy, Hypertrophic pathology, Cardiomyopathy, Hypertrophic physiopathology, Death, Sudden, Cardiac etiology, Death, Sudden, Cardiac prevention & control, Female, Fibrosis, Humans, Logistic Models, Male, Middle Aged, Myocardium pathology, Predictive Value of Tests, Retrospective Studies, Risk Assessment, Risk Factors, Tachycardia, Ventricular diagnosis, Tachycardia, Ventricular physiopathology, Tachycardia, Ventricular therapy, Young Adult, Cardiomyopathy, Hypertrophic diagnostic imaging, Computer Simulation, Magnetic Resonance Imaging, Tachycardia, Ventricular etiology
- Abstract
Hypertrophic cardiomyopathy (HCM) is associated with risk of sudden cardiac death (SCD) due to ventricular arrhythmias (VAs) arising from the proliferation of fibrosis in the heart. Current clinical risk stratification criteria inadequately identify at-risk patients in need of primary prevention of VA. Here, we use mechanistic computational modeling of the heart to analyze how HCM-specific remodeling promotes arrhythmogenesis and to develop a personalized strategy to forecast risk of VAs in these patients. We combine contrast-enhanced cardiac magnetic resonance imaging and T1 mapping data to construct digital replicas of HCM patient hearts that represent the patient-specific distribution of focal and diffuse fibrosis and evaluate the substrate propensity to VA. Our analysis indicates that the presence of diffuse fibrosis, which is rarely assessed in these patients, increases arrhythmogenic propensity. In forecasting future VA events in HCM patients, the imaging-based computational heart approach achieved 84.6%, 76.9%, and 80.1% sensitivity, specificity, and accuracy, respectively, and significantly outperformed current clinical risk predictors. This novel VA risk assessment may have the potential to prevent SCD and help deploy primary prevention appropriately in HCM patients., Competing Interests: RO, EB, AP, SZ, MC, MA, DL, PB, NT No competing interests declared, (© 2022, O'Hara et al.)
- Published
- 2022
- Full Text
- View/download PDF